共查询到20条相似文献,搜索用时 234 毫秒
1.
目的评价吉西他滨联合顺铂(GP方案)治疗老年晚期非小细胞肺癌的临床疗效与毒副反应。方法对30例经病理和(或)细胞确诊的老年晚期非小细胞肺癌患者,采用吉西他滨联合顺铂化疗。吉西他滨1000mg/m^2,静脉点滴,第1,8天各静滴1次;顺铂25mgc/m^2,静脉点滴,第1,2,3天各静滴1次,每28d为一个周期,化疗中记录毒副反应。2个周期为1个疗程。疗程结束后,评定疗效与毒副反应。结果全组完全缓解(CR)0例,部分缓解11例(11/30),总有效率36.67%。最常见的毒副反应为白细胞减少和血小板减少。结论吉西他滨联合顺铂方案治疗老年晚期非小细胞肺癌患者临床疗效较好,毒副反应可耐受,值得推广应用。 相似文献
2.
目的观察以吉西他滨联合顺铂治疗晚期非小细胞肺癌的疗效和毒副作用。方法35例晚期非小细胞肺癌用吉西他滨(GEM)1000mg/m^2 d1,d8静脉滴注,顺铂(DDP)20mg静脉滴注d1~5或80mg/m^2静脉滴注d1,3周重复,2~3周期后按WHO标准评价疗效。结果35例患者中CR1例,PR16例,NC14例,PD4例。总有效率48.6%主要毒副作用是骨髓抑制和消化道反应。结论吉西他滨联合顺铂治疗晚期非小细胞肺癌的疗效是较高的。 相似文献
3.
目的探讨吉西他滨联合顺铂治疗晚期非小细胞肺癌的安全性和疗效。方法回顾性分析该院经过GP方案(吉西他滨联合顺铂)治疗的68例晚期非小细胞肺癌的临床资料。对68例晚期非小细胞肺癌患者采用吉西他滨1000mg/m2静脉滴注,第1天和第8天,顺铂25mg/m2,静脉滴注,第1—3天,21~28d为一个周期,2个周期后对患者病情进行一次疗效评价。结果68例患者中完全缓解(CR)4例(5.9%),部分缓解(PR)27例(39.7%),稳定(SD)33例(48.5%),进展(PD)4例(5.9%),总有效率为45.6%(31/68);鳞癌有效率为46.7%(14/30),腺癌有效率为52.6%(20/38)。缓解期为(4.6±3.4)个月,1年生存率为44.1%(30/68)。结论吉西他滨联合顺铂治疗晚期非小细胞肺癌疗效好,副作用小,临床上值得推广应用。 相似文献
4.
目的观察不同剂量、用法的吉西他滨联合顺铂治疗晚期非小细胞肺癌对骨髓抑制的影响情况。方法将45例经病理或细胞学证实的晚期非小细胞肺癌患者分为A、B两组。A组:吉西他滨1000mg/m^2,静脉滴注,第1,8,15天,顺铂每日30mg,第1-4天,静脉滴注,28d为1周期;B组:吉西他滨1250mg/m^2,静脉滴注,第1,8天,用法同前,21d为1周期,连用至少2个周期方可评价。结果白细胞下降B组较A组明显,但P〉0.05,无统计学意义,血小板减少A组也较B组显著,P〈0.05,差异有统计学意义。结论两种方案治疗晚期非小细胞肺癌疗效大致相等,但B组对骨髓抑制的影响明显减少,更易耐受,值得临床应用推广。 相似文献
5.
三维适形放疗联合GP方案同步治疗局部晚期非小细胞肺癌临床观察 总被引:3,自引:1,他引:2
目的探讨三维适形放疗联合GP方案同步化疗治疗局部晚期非小细胞肺癌的近期疗效和急性毒副反应。方法40例Ⅲ期非小细胞肺癌患者采用三维适形放疗,同时予GP方案化疗(G:吉西他滨1000mg/m^2,第l,8天;P:顺铂30mg/m^2,第1-3天,每28天1个周期)。结果肺原发灶总有效率为85%;纵隔转移淋巴结总有效率为91.9%,急性毒副反应主要是骨髓抑制、胃肠道反应和轻中度放射性食管炎、放射性肺炎,均可耐受。结论三维适形放疗与GP方案同步放化疗治疗局部晚期非小细胞肺癌有较好近期疗效。 相似文献
6.
奈达铂联合化疗治疗晚期非小细胞肺癌 总被引:3,自引:1,他引:2
目的评价奈达铂联合长春瑞滨治疗晚期非小细胞肺癌的疗效和不良反应。方法对28例初治晚期非小细胞肺癌行奈达铂联合长春瑞滨化疗,方案:奈达铂80mg/m^2静滴d1。长春瑞滨25mg/m^2静注d1、d8,3~4周为一周期,用药4周期。对照组25例,化疗方案为顺铂加长春瑞滨。结果奈达铂组PR11例,有效率(CR+PR)为39.2%;对照组CR1例、PR8例,有效率40.0%,两组间差异不明显(P〉0.05);毒性反应白细胞与血小板减少治疗组与对照组无显著性差别(P〉0.05);消化道反应奈达铂组明显小于顺铂组(P〈0.05)。结论奈达铂联合化疗治疗晚期非小细胞肺癌的疗效与顺铂相当,消化道毒性小于顺铂。奈达铂联合长春瑞滨化疗是治疗晚期小细胞肺癌较为有效的化疗方案之一。 相似文献
7.
目的评价国产吉西他滨联合顺铂治疗晚期复治非小细胞肺癌的疗效和毒副反应。方法21例有病理或细胞学诊断的晚期非小细胞肺癌患者,给予国产吉西他滨0.8g/m2d1,5静脉点滴;顺铂40m g/m2d1-3静脉滴注。21天重复,2周期后评价疗效和毒副反应。结果CR 0例,PR 7例,SD 6例,PD 8例,有效率33.3%。生活质量改善。不良反应主要为骨髓抑制,消化道反应、发热和皮疹。结论国产吉西他滨联合顺铂方案治疗晚期复治非小细胞肺癌,疗效较好,毒副反应能耐受。 相似文献
8.
吉西他滨联合顺铂治疗老年性晚期非小细胞肺癌临床观察 总被引:1,自引:1,他引:1
目的评价吉西他滨联合顺铂治疗老年性晚期非小细胞肺癌(Nscle)的近期疗效及毒副作用。方法对33例不能手术的老年性晚期Nscle患者采用GP方案,完成两周期后进行疗效评价。结果33例CR6.6%,PR36.6%,SD39.3%,PD18.8%,总有效率(CR PR)42.4%。结论吉西他滨联合顺铂治疗老年性晚期非小细胞肺癌疗效较好,毒性作用可以耐受。 相似文献
9.
吉西他滨联合铂类治疗晚期非小细胞肺癌的临床分析 总被引:5,自引:0,他引:5
目的评价吉西他滨联合不同铂类化疗药物治疗ⅢB~Ⅳ期非小细胞肺癌(NSCL)的临床疗效和毒副反应。方法45例经细胞学或病理学证实ⅢB~Ⅳ期NSCLC患者(初治35例,复治10例),患者的预计生存时间均超过2个月。按三种方案联合化疗:(1)吉西他滨+顺铂(GEM/DDP),每3周重复1次;(2)吉西他滨+卡铂(GEM/CBP),每3周重复1次;(3)吉西他滨+顺铂(GEM/DDP),每4周重复1次。按美国癌症研究所(NCI)实体瘤疗效评价标准(Recist标准)对目标病灶评价,毒性反应按2007中国肺癌临床指南(NCI—CTCV2.0)标准进行评价。随访患者中位生存时间并计算1年生存率。结果共完成158个周期全身化疗,平均每个病人接受3.5个周期化疗。吉西他滨联合顺铂3周及4周方案、吉西他滨联合卡铂三种方案的有效率分别为45.8%(11/24)、45.5%(5/11)和50%(5/10),总有效率为46.7%(21/45),35例初治患者中有效18例,有效率51.4%,10例复治患者中有效3例,有效率30%。毒副反应主要为白细胞减少、血小板减少、消化道反应、皮疹和搔痒。中位生存时间(MST)为8.9个月,1年生存率为38.7%。结论吉西他滨联合铂类化疗药物治疗晚期NSCL疗效较好,且毒性反应少,耐受性好。 相似文献
10.
紫杉醇联合化疗治疗晚期非小细胞肺癌43例疗效观察 总被引:1,自引:0,他引:1
目的 评价紫杉醇联合顺铂或卡铂对晚期非小细胞肺癌的疗效和毒副作用。方法 43例晚期非小细胞肺癌应用紫杉醇175mg/m^2和顺铂80mg/m^2或卡铂350mg/m^2联合化疗,每3-4周一次,2-3周期为一疗程。结果 43例总有效率39.5%,紫杉醇加顺铂29例,有效率44.8%;紫杉醇加卡铂14例,有效率为28.6%。复治病例14例,有效率42.9%。主要毒副作用是骨髓抑制、脱发、手足麻木、关节肌肉瘤、心脏毒性反应。结论 紫杉醇联合顺铂或卡铂是治疗晚期非小细胞肺癌的有效方案,安全且耐受。 相似文献
11.
12.
13.
目的探讨培美曲塞(PMT)联合顺铂(DDP)治疗晚期非鳞型非小细胞肺癌(NSCLC)的疗效及不良反应。方法收集92例经病理组织学或细胞学确诊的晚期非鳞型NSCLC患者,将其随机分为观察组和对照组,观察组42例,接受PMT联合DDP方案化疗:PMT 500 mg/m2静滴,第1天,联合DDP 25 mg/m2第1-3天。对照组50例,接受多西他赛(DOC)联合DDP方案化疗:DPC 75 mg/m2静滴,第1天,联合DDP 25 mg/m2第1-3天。2组治疗周期均为每3周1次。每例患者均治疗>2个周期,观察2组疗效和不良反应。结果 92例患者完全缓解(CR)5例,部分缓解(PR)34例,稳定(SD)39例,进展(PD)14例。观察组总有效率为52.4%,对照组总有效率为34.0%,2组间比较无统计学差异;观察组主要不良反应包括骨髓抑制、胃肠道反应、脱发等,发生率显著低于对照组(P〈0.05或0.01),且以Ⅰ-Ⅱ级为主。结论 PMT联合DDP方案治疗晚期非鳞型NSCLC疗效与DOC联合DDP方案的疗效相当,但PMT联合DDP的不良反应发生率低,耐受较好。 相似文献
14.
Reck M von Pawel J Nimmermann C Groth G Gatzemeier U 《Pneumologie (Stuttgart, Germany)》2004,58(12):845-849
Despite improvements in chemotherapy of advanced and metastatic Non-Small-Cell-Lung-Cancer (NSCLC) the prognosis of these patients still remains poor with a 5-year-survival of 2 to 5 %. Due to the high level of hypoxic cells in solid tumors agents with activity in hypoxic milieu as the Benzotriazine compound Tirapazamine (SR 259 075) might improve the therapeutic results. We treated 45 patients with advanced or metastatic Non-Small-Cell-Lung-Cancer (stage IIIb: 20 patients, stage IV: 25 patients) with the combination TPZ 330 mg/m (2) (day 1), Cisplatin 75 mg/m (2) (day 1) and Gemcitabine 1250 mg/m (2) (day 1 and 8) every 3 weeks. With a response rate of 40 % median progression free survival was 6.7 months (4.8 - 8.1 months) and median survival was 8.1 months (7.5 - 12.5 months), (1-year-survival: 35 %). Hematologic and non-hematologic toxicity was moderate (neutropenia CTC grade 3 and 4: 20 %, thrombocytopenia CTC grade 3 and 4: 16 %, nausea and vomiting CTC 3: 5 %). Treatment of advanced and metastatic NSCLC with TPZ in combination with Gemcitabine/Cisplatin was well feasible and showed results recording to currently published data. The results of a following phase III-trial are awaited. 相似文献
15.
A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer 总被引:5,自引:0,他引:5
STUDY OBJECTIVE: Vinorelbine and gemcitabine are two active single agents used in the treatment of non-small cell lung cancer (NSCLC). A clinical trial was conducted to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine in patients with inoperable (stage IIIB or IV) NSCLC. DESIGN: A multicenter phase II study. Vinorelbine, 20 mg/m(2), was given as a 10-min IV infusion, followed by a 30-min IV infusion of gemcitabine, 800 mg/m(2), on days 1, 8, and 15 of each 28-day cycle. PATIENTS AND MEASUREMENTS: From March 1998 to August 1998, 40 patients were enrolled in the study. The efficacy and toxicity of the treatment were recorded. RESULTS: All patients are evaluable for treatment response and toxicity profile. Two patients achieved a complete response, and 27 patients achieved a partial response, with an overall response rate of 72.5% (95% confidence interval, 58.7 to 86.3%). Median survival time was 11 months. The significant (World Health Organization grade, 3/4) toxicities were myelosuppression, including leukopenia (47.5% of patients), anemia (17.5% of patients), and thrombocytopenia (12.5% of patients). However, febrile neutropenia occurred in three patients and accounted for one treatment-related death. Fatigue, or flu-like syndrome, occurred in 17 patients, and the symptoms were reversed spontaneously 1 to 2 days after injection in 10 patients. Another seven patients needed dose reduction to ameliorate symptoms. Interstitial pneumonitis occurred in six patients who recovered after steroid treatment. No patient suffered from grade 3 or 4 nausea/vomiting. CONCLUSION: The combination of vinorelbine and gemcitabine in patients with advanced NSCLC is a highly active non-cisplatin-containing regimen with an acceptable toxicity profile. 相似文献
16.
Gastric cancer is the second most common among cancer-related deaths in the world. Systemic chemotherapy for patients with gastric cancer has limited impact on overall survival. We performed a retrospective analysis of the efficacy and side effects of Docetaxel and Cisplatin Plus Fluorouracil (DCF) versus Modified-Dose Docetaxel, Cisplatin, and 5-Fluorouracil (mDCF) in the metastatic gastric cancer with first-line chemotherapy treated patients. Retrospectively were reviewed 107 locally advanced or metastatic gastric cancer patients who were treated DCF or mDCF as first-line treatment from June 2007 to August 2011 in Dicle University Hospital, Department of Medical Oncology.The DCF protocol included 75 mg/m2 docetaxel and cisplatin on day 1 and 750 mg/m2/day 5-FU infusion for 5 days, repeated every 3 weeks. The mDCF protocol included 60 mg/m2 docetaxel and cisplatin on day 1 and 600 mg/m2 5-Fluorouracil continuous infusion per day on days 1-5, every 3 weeks.Patients were treated using DCF arm 85 (M: 56, F: 29), the mDCF arm 22 (M: 13, F: 9) After treatment toxicities were: Grade III-IV neutropenia (48.2% vs 13.6% p=0.003), anemia (21.2% vs 4.5% p=0.06), nausea (44.7% vs 13.6% p=0.008) and vomiting (31.8% vs 4.5%, p=0.01) was higher in the DCF arm. Other toxicities profile was similar in both groups (p>0.05). The rate of response was similar in both arm. Among patients with the DCF and mDCF arm rate complete response (10.3% vs 6.7%, p>0.05), partial response (35.3% vs 40.0%, p>0.05), stable disease (32.4% vs 33.3%, p>0.05), progressive disease (22.1% vs 20.0%, p>0.05) and overall response (45.6% vs 46.7%, p>0.05) did not have a statistically difference (p>0.05). Progression-free survival (PFS) and overall survival (OS) were more favorable in the DCF arm than mDCF arm, but the difference was not significant statistically (9.9 vs 8.6, 7.4 vs 6.5 p>0.05)In conclusion, the response rate, median PFS and median OS are similar in both arms, while the mDCF regimen are more favorable than the DCF for toxicity profile regimen in advanced gastric cancer patients who were undergoing first-line palliative treatment. Therefore, a prospective and larger clinical trials are needed. 相似文献
17.
紫杉醇单药及联合顺铂治疗老年晚期非小细胞肺癌的临床观察 总被引:2,自引:1,他引:1
目的观察紫杉醇(TAX)单药与TAX+顺铂(DDP)治疗老年晚期NSCLC的疗效和不良反应。方法经病理学或细胞学证实的58例晚期非小细胞肺癌随机分为两组,A组:应用TAX单药化疗,B组:TAX+DDP联合化疗,21天为一个周期,均治疗2周期以上。观察经两方案治疗后的缓解率(RR)、临床获益率(CR+PR+SD)、1年生存率和不良反应。结果A组及B组的有效率分别为31.0%和37.9%(P=0.22);临床获益率(CR+PR+SD)分别为72.4%和79.3%(P=0.73);1年生存率分别为43.3%和46.4%(P=0.52);单药组的消化道毒性、骨髓毒性及肾脏损伤均显著低于联合组(P〈0.05)。结论紫杉醇单药或联合顺铂均是治疗老年晚期NSCLC的较好方案,二者疗效相似,单药紫杉醇毒副反应更少见,较易为老年患者接受。 相似文献
18.
Tsutsumi S Yamaguchi S Ide M Tsuboi K Fukasawa T Yamaki S Asao T Kuwano H 《Hepato-gastroenterology》2006,53(68):196-200
BACKGROUND/AIMS: A phase I clinical trial has been planned to determine the recommended dose and to assess the safety and efficacy of combination chemotherapy of S-1 with cisplatin and irinotecan (SCI regimen) as a second-line treatment in 5-fluorouracil (5-FU) resistant colorectal cancer (CRC). METHODOLOGY: Patients with unresectable recurrent or metastatic CRC were enrolled in this study for second-line treatment. On an outpatient basis, the patients received a treatment SCI regimen comprising S-1 oral administration for 28 days followed by withdrawal for 2 weeks, plus cisplatin and irinotecan were administered on days 1, 8, 15 and 22 by intravenous injection. These courses were repeated every 6 weeks. Starting doses were 70 mg/m2 S-1, 6 mg/m2 Cisplatin, and 60 mg/m2 Irinotecan. RESULTS: A total of 29 patients was enrolled. Dose-limiting toxicities were fatigue, nausea, and leucopenia. Twenty-three patients at recommended dose were evaluable for treatment response. The response rate was 21.7% (5 partial responses, 13 stable diseases, and 5 progressive diseases). The median progression-free survival rate was 4.3 months; the median survival time was 9.6 months. CONCLUSIONS: The SCI regimen is feasible in an outpatient setting and should be considered as second-line chemotherapy for patients with 5-FU resistant CRC. 相似文献
19.
目的 观察国产异长春花碱(盖诺)加顺铂治疗晚期非小细胞肺癌的疗效及毒副反应。方法 共治疗48例患者,男性35例,女性13例。病理类型以腺癌为主(23例),Ⅲb期30例,Ⅳ期18例。34例初治,14例复治。异长春花碱25mg/m^2静点,第1、8天,顺铂30mg/m^2静点,第1~3天,3周为1周期,化疗2~3周期后评价疗效。结果 完全缓解(CR)1例,部分缓解(PR)17例,无变化(NC)21例,进展(PD)9例,有效率(CR PR)37.50%(18/48)。毒副反应主要为自细胞减少、恶心呕吐及静脉炎。结论 国产异长春花碱加顺铂治疗晚期非小细胞肺癌,疗效较高且毒副反应可以耐受。 相似文献
20.
国产多西他赛联合顺铂治疗晚期非小细胞肺癌疗效观察 总被引:2,自引:1,他引:1
目的观察国产多西他赛联合顺铂(DDP)治疗晚期非小细胞肺癌的近期疗效、临床受益和毒副反应。方法70例晚期NSCLC患者给予DP方案化疗:国产多西他赛75mg/m^2,静滴,d1;顺铂75mg/m^2,静滴,d1;21d为1周期。每例患者治疗2周期以上。结果全组完全缓解2例,部分缓解29例,稳定36例,进展3例,总有效率44.3%。中位生存期10.1个月,1年生存率38.6%(27/70)。临床受益疗效:行为状态阳性率51.4%,体重阳性率47.1%。毒副反应主要为骨髓抑制,脱发和消化系统反应。其中白细胞减少占75.7%,G-CSF治疗后较快恢复。结论国产多西他赛联合顺铂无论一线还是二线治疗晚期NSCLC近期疗效和临床受益良好,毒副反应可耐受。 相似文献